Mytatrienediol
http://dbpedia.org/resource/Mytatrienediol an entity of type: Thing
Mytatrienediol (developmental code name SC-6924; former tentative brand names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a synthetic steroidal estrogen medication and an estrogen ether which was derived from estriol and was developed for clinical use in the late 1950s but was never marketed. It was investigated as a weak and mildly estrogenic medication for men to treat atherosclerosis, improve serum lipid profiles, and reduce the risk of myocardial infarction. However, while preclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found in clinical trials to produce estrogenic side effects including feminization, breast pain, and gynecomastia in men similarly and c
rdf:langString
rdf:langString
Mytatrienediol
xsd:integer
51508304
xsd:integer
1084549142
xsd:integer
20
xsd:integer
5108
xsd:integer
34859
xsd:integer
4445527
xsd:integer
28
xsd:integer
-3
<nicaraguanCórdoba>
14242.0
xsd:integer
3
xsd:integer
5282364
rdf:langString
CC12CCC3CCCC4=C3C=CCOC
xsd:integer
1
rdf:langString
OOVXZFCPCSVSEM-NADOGSGZSA-N
rdf:langString
SC-6924; Manvene; Anvene; (3-Methoxy-16α-methylestra-1,3,5-triene-16β,17β-diol; 16α-Methylestriol 3-methyl ether; 16β-Hydroxy-16α-methylestradiol 3-methyl ether)
xsd:integer
1
xsd:integer
225
rdf:langString
Mytatrienediol (developmental code name SC-6924; former tentative brand names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a synthetic steroidal estrogen medication and an estrogen ether which was derived from estriol and was developed for clinical use in the late 1950s but was never marketed. It was investigated as a weak and mildly estrogenic medication for men to treat atherosclerosis, improve serum lipid profiles, and reduce the risk of myocardial infarction. However, while preclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found in clinical trials to produce estrogenic side effects including feminization, breast pain, and gynecomastia in men similarly and comparably to other estrogens such as ethinylestradiol and conjugated estrogens, and its side effects ultimately precluded its use. The medication was also studied to treat bone pain in patients with multiple myeloma, metastatic bone disease, and osteoporosis, with effectiveness seen.
xsd:nonNegativeInteger
7285
xsd:string
5108-94-1
xsd:string
34859
xsd:string
1G3TKH1O14
xsd:string
C14242
xsd:string
5282364